These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 10336580

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.
    Cai WM, Chen B, Zhou Y, Zhang YD.
    Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites.
    Rouini MR, Afshar M.
    Therapie; 2017 Jun; 72(3):373-382. PubMed ID: 28087064
    [Abstract] [Full Text] [Related]

  • 6. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
    Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P, Rzemislawska Z, Loboz-Grudzien K, Dmochowska-Perz M, Slawin J.
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis.
    Tran QT, Baek IH, Han NY, Yun HY, Chae JW.
    Pharmaceutics; 2022 Jul 11; 14(7):. PubMed ID: 35890339
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M.
    Pharmacogenetics; 1999 Oct 11; 9(5):551-9. PubMed ID: 10591535
    [Abstract] [Full Text] [Related]

  • 12. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
    Dilger K, Meisel P, Hofmann U, Eichelbaum M.
    Ther Drug Monit; 2000 Jun 11; 22(3):366-8. PubMed ID: 10850406
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous determination of propafenone and 5-hydroxypropafenone enantiomers in plasma by chromatography on an amylose derived chiral stationary phase.
    Pires de Abreu LR, Lanchote VL, Bertucci C, Cesarino EJ, Bonato PS.
    J Pharm Biomed Anal; 1999 Jun 11; 20(1-2):209-16. PubMed ID: 10704025
    [Abstract] [Full Text] [Related]

  • 14. Enantioselective assay of S+ - and R- -propafenone in human urine by using RP-HPLC with pre-column chiral derivatization.
    Wu YJ, Ma MM, Zheng S.
    J Zhejiang Univ Sci; 2004 Feb 11; 5(2):226-9. PubMed ID: 14674037
    [Abstract] [Full Text] [Related]

  • 15. Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.
    Anzenbacherová E, Anzenbacher P, Perlik F, Kvetina J.
    Int J Clin Pharmacol Ther; 2000 Sep 11; 38(9):426-9. PubMed ID: 11020029
    [Abstract] [Full Text] [Related]

  • 16. Enantioselective determination of propafenone and its metabolites in human plasma by liquid chromatography-mass spectrometry.
    Zhong D, Chen X.
    J Chromatogr B Biomed Sci Appl; 1999 Jan 08; 721(1):67-75. PubMed ID: 10027638
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
    Cai WM, Zhang YD, Chen B, Cai MH, Luo JP, Ling SS.
    Acta Pharmacol Sin; 2001 Oct 08; 22(10):956-60. PubMed ID: 11749782
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.